medigraphic.com
ISSN 1561-3070 (Digital)

2014, Número 3

<< Anterior Siguiente >>

Rev Cub Oftal 2014; 27 (3)


Uso de HeberPAG en carcinoma basocelular periocular

Jiménez BY, Vega PC, Vila PD, Fernández YG, Arias NV, Bello RI

Idioma: Español
Referencias bibliográficas: 26
Paginas: 482-489
Archivo PDF: 418.14 Kb.


RESUMEN

Se describe el caso clínico de un paciente de 34 años de edad con un carcinoma basocelular nodular de párpado inferior del ojo izquierdo, de 3 años de evolución. Se procedió a aplicar el HeberPAG en inyección perilesional 3 veces por semana durante 3 semanas consecutivas. Terminadas las aplicaciones de este producto desaparecieron los signos clínicos del tumor. Se comenta el potencial destructor de este tumor, así como las técnicas utilizadas en el manejo de esta patología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmstead County, Minnesota. Ophthalmology. 1999;106(4):746-50.

  2. Gonzales F, García A. Carcinoma Basocelular Periocular. Madrid: Arch Soc Esp Oftalmol. 2005;80(5):275‐82.

  3. Anuario Demográfico de Cuba; 2010 [citado 20 de enero de 2014]. p. 109-17. Disponible en: http://www.one.cu/publicaciones/cepde/anuario_2010/ anuario_capitulo_pob lacion.pdf

  4. Tatiana KSC. Predisposing factors and outcomes of malignant skin tumors in children. Plast Reconstr Surg. 2010;126(2). p. 508-14.

  5. García Martín E, Fernández Tirado FJ. Tendencias en el tratamiento de los CBC perioculares Arc Soc Esp. 2010 [citado 25 de marzo de 2014];85(8):261-2. Disponible en: www.elseiver.es/oftalmología

  6. Colectivo de autores. Tumores palpebrales. Manual de diagnóstico y tratamiento en oftalmología. Educación Médica Superior. 2009 [citado 12 de abril de 2014];23(3). p. 131-37. Disponible en: http://scielo.sld.cu/pdf/ems/v23n3/ ems12309.pdf

  7. Ainbinder DJ, Esmaeli B, Groo SC, Finger PT, Brooks JP. Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual. Arch Pathol Lab Med. 2009;133(8):1256-61.

  8. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A, Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131.

  9. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63(4). p. 689-702.

  10. Iki D, Padovan I, Pipic N, Kneievi M, Djakovic N, Rode B, Koutic I. Treatment of squamous cell carcinoma with lnterferon. Internat J Dermatol. 2007;30(1). p . 58-61.

  11. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011. 64(2): p. 413-22.

  12. Anasagasti Angulo L, García Vega Y, Barcelona Pérez S. Treatment of advance, recurrent, resistant tto previous treatment basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262:1471-2407.

  13. Smith V, Walton S. Treatment of facial basal cell carcinoma: A review. Hindawi Publishing Corporation.Journal of Skin Cancer. 2011. ID 380371, doi:10.1155/2011/380371.

  14. Char DH. Tumors of the eye and ocular adnexa. Londres: BC Decker Inc.; 2001.

  15. Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342-6.

  16. Olbricht SM. Treatment of malignant cutaneous tumors. Clin Plast Surg. 1993;20:167-80.

  17. Orenberg EK, Miller BH, Greenway HT, Koperski JA, Lowe N, Rosen T et al. The effect of intralesional 5-fluoracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol. 1992;27:723-8.

  18. Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. N Engl J Med. 1990;323:789-95.

  19. Wang I, Bauer B, Anderson-Engels S, Svanberg S, Svanberg K. Photodynamic therapy utilising topical delta-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin. Acta Ophthalmol Scand. 1999;77:182-8.

  20. Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer. 1998;20:167-80.

  21. Chang BK, Guthrie TH Jr, Hayakawa K, Gangarosa LP. A pilot study of iontophoretic cisplatin chemotherapy of basal and squamous cell carcinomas of the skin. Arch Dermatol. 1993;129:425-7.

  22. Bullock JD, Beard C, Sullivan JH. Cryotherapy of basal cell carcinoma in oculoplastic surgery. Am J Ophthalmol. 1976;82:841-7.

  23. Fitzpatrick PJ, Jamieson DM, Thompson GA, Allt WE. Tumors of the eyelids and their treatment by radiotherapy. Radiology. 1972;104:661-5.

  24. Sacchini V, Lovo GF, Arioli N, Nava M, Bandieramonte G. Carbon dioxide laser in scalp tumor surgery. Laser Surg Med. 1984;4:261-9.

  25. Fenton S, Kennedy S, Moriarty P. The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmol Scand. 2002;80:674-5.

  26. Huerva V, Mangues I. Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary at the primary treatment with intralesional interferon alpha 2b. Ind J Ophthalmol. 2008;56:85-6.




2020     |     www.medigraphic.com